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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• The CYP3A4 inhibition by lipophilic statins
may attenuate the effectiveness of
clopidogrel.
• No studies have measured drug exposure in
a time-varying manner that detects
discontinuation and restart of clopidogrel
and statin therapy, allowing clinical
quantification of the interaction effect.
WHAT THIS STUDY ADDS
• Clopidogrel and CYP3A4-metabolizing statin
use were each associated with a
substantially reduced rate of major adverse
cardiovascular events within 12 months
after coronary stent implantation.
• Although we observed an interaction
between use of clopidogrel and statins,
statin use vs. non-use was not associated
with an increased rate of major adverse
cardiovascular events in patients using
clopidogrel after coronary stent
implantation.
AIMS
To examine whether CYP3A4-metabolizing statin use modified the association
between clopidogrel use and major adverse cardiovascular events (MACE) after
coronary stent implantation, using time-varying drug exposure ascertainment.
METHODS
We conducted this population-based cohort study in Western Denmark
(population: 3 million) using medical databases. We identified all 13 001 patients
with coronary stent implantation between 2002 and 2005 and their
comorbidities. During 12 months of follow-up, we tracked the use of clopidogrel
and CYP3A4-metabolizing statins and the rate of MACE. We used Cox regression
to compute hazard ratios (HRs) controlling for potential confounders.
RESULTS
The rate of MACE per 1000 person years was 104 for concomitant clopidogrel
and statin use, 130 for clopidogrel without statin use, 108 for statin without
clopidogrel use and 446 for no use of either drug. The adjusted HR comparing
clopidogrel use with non-use was 0.68 (95% confidence interval (CI) 0.58, 0.79)
among statin users and 0.34 (95% CI 0.29, 0.40) among statin non-users, yielding
an interaction effect (i.e. relative rate increase) of 1.97 (95% CI 1.59, 2.44). The
adjusted HR for MACE comparing statin use with non-use was 0.97 (95% CI 0.83,
1.13) among clopidogrel users and 0.49 (95% CI 0.42, 0.57) among clopidogrel
non-users.
CONCLUSIONS
Clopidogrel and CYP3A4-metabolizing statin use were each associated with a
substantially reduced rate of MACE within 12 months after coronary stent
implantation. Although we observed an interaction between use of clopidogrel
and statins, statin use vs. non-use was not associated with an increased rate of
MACE in patients using clopidogrel after coronary stent implantation.
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Introduction
Currently the thienopyridine clopidogrel is a mainstay in
the treatment of vascular events in patients with coronary
artery disease or ischaemic stroke [1]. Clopidogrel is a pro-
drug metabolized by hepatic cytochrome P450 (CYP)
enzymes (primarily the 2C19 and 3A4 isoforms) to an
active thiol metabolite, which irreversibly inhibits
adenosine-5-diphosphate (ADP) binding to the platelet
P2Y12-receptor. Debate is ongoing about possible inter-
actions between clopidogrel and other commonly
used drugs [2], including 3-hydroxy-3-methylglutaryl
coenzyme-A reductase inhibitors (statins) that are widely
used to lower cholesterol concentrations [2]. In several
ex vivo studies, two CYP3A4-metabolizing statins, atorvas-
tatin [3–5] and simvastatin [6], have been reported to
diminish the antiplatelet effect of clopidogrel, but these
findings have not convincingly been confirmed in clinical
settings [7–15]. None of the previous studies have mea-
sured drug exposure in a time-varying manner that
detects discontinuation and restart of clopidogrel and
statin therapy, allowing clinical quantification of the inter-
action effect [16].
The clinical importance of a possible clopidogrel–statin
interaction arises from the large number of percutaneous
coronary interventions (PCIs) performed annually, the
increasing use of drug-eluting stents that necessitate long
term treatment with clopidogrel [1], and the fact that any
adverse interaction may be prevented by avoiding
co-administration of clopidogrel and a statin.We therefore
conducted a population-based cohort study with com-
plete 12 month follow-up, taking into consideration
comorbidity, time-varying medication use and multiple
outcomes. We examined whether statin use modified the
association between clopidogrel use and major adverse
cardiovascular events (MACE) after coronary stent implan-
tation, and whether clopidogrel users were at increased
risk of MACE when co-administered a statin.
Methods
Setting
We conducted this population-based cohort study using
medical databases in Western Denmark, which has three
million inhabitants (55% of the Danish population) [17].
The Danish National Health Service provides universal tax-
supported health care, guaranteeing unfettered access to
general practitioners and hospitals, and partial reimburse-
ment for prescribed medications, including clopidogrel
and statins [18]. Accurate and unambiguous linkage of all
registries at the individual level is possible in Denmark
using the unique central personal registry number
assigned to each Danish citizen at birth and to residents
upon immigration [19].
As this study did not involve any contact with patients
or any intervention, it was not necessary to procure per-
mission from the Danish Scientific Ethical Committee.
Patients and procedures
We used the Western Denmark Heart Registry (WDHR) to
identify all PCIs performed between 1 January 2002 and 30
June 2005 in the study region [17]. Since 1999 this registry
has collected patient and procedure data from all cardiac
intervention centres in Western Denmark [17]. We defined
the first PCI during the inclusion period as the ‘index PCI’
and the date of the procedure as the ‘index date’. We did
not include patients treated with balloon angioplasty
without stenting.
The participating centres were high volume facilities,
each performing more than 1000 PCIs per year. The inter-
ventions were performed according to current standards,
with the interventional strategy (including balloon angio-
plasty, pre- or post-dilatation, choice of stent, direct stent-
ing, administration of periprocedural glycoprotein IIb/IIIa
inhibitor) left to the operator’s discretion [17].
Medication use
We used the Danish Nationwide Prescription Database
(DNPD) [20] to identify prospectively all filled prescriptions
for clopidogrel and statins [21]. Thienopyridines and
statins are available by prescription only. As no prescrip-
tions were filled for ticlopidine,no alternative ADP receptor
inhibitor was included in the study. Associated Anatomical
Therapeutic Chemical (ATC) codes are provided in the
Appendix.
The recommended daily maintenance dose of clopi-
dogrel for secondary prevention of ischaemic vascular
events in Denmark is 75 mg (one tablet) daily for up to 12
months [21]. Thus, for study purposes the number of days
supplied from a dispensed clopidogrel prescription corre-
sponded to the number of tablets per package. Available
packages on the Danish market contain 28 or 84 tablets
[21].We computed the number of days exposed by adding
7 days to the number of days supplied. This buffer allowed
for a 7 day gap to occur between prescription fillings
before a patient was considered to have discontinued the
medication.
We grouped the CYP3A4-metabolizing statins (simvas-
tatin, lovastatin and atorvastatin) into one main exposure
group [22]. As in the case of clopidogrel, we computed the
number of days exposed for statins. For clopidogrel and
statins individually, we defined current users at a given
point in time as patients exposed by the most recent filled
prescription. In a time-varying manner, patients thus con-
tributed time-at-risk as a current or as a non-user of each
drug.
Major adverse cardiovascular events
In line with the recommended duration of clopidogrel
treatment [21], we identified MACE occurrences within 12
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months after the index date. We defined MACE as a first
occurrence of myocardial infarction (MI), ischaemic stroke,
stent thrombosis, target lesion revascularization or cardiac
death. A committee of cardiac specialists, blinded to the
history of medication use, reviewed relevant records to
determine the occurrence of stent thrombosis and cardiac
death, which originally were not included in the medical
registries [17].
Myocardial infarction and ischaemic stroke
We used the Danish National Registry of Patients (DNRP)
[23], covering all non-psychiatric hospitals since 1977, and
emergency room and outpatient clinic visits since 1995, to
identify admissions for MI and ischaemic stroke [24]. Asso-
ciated International Classification of Diseases (ICD) codes
are provided in the Appendix.
Stent thrombosis and target lesion
revascularization
Based on review of original medical records and catheter-
ization angiograms, the cardiac specialist committee adju-
dicated the occurrence of definite stent thrombosis as
defined by the Academic Research Consortium [17]. We
defined target lesion revascularization (TLR) as a repeat PCI
or coronary artery bypass grafting of the index lesion, iden-
tified from the WDHR [17].
Cardiac death
We obtained data on all cause mortality from the Danish
Civil Registration System [19]. This registry has recorded
vital statistics, including date of birth, change of address,
date of emigration and exact date of death, for the Danish
population since 1968 [19]. The cardiac specialist commit-
tee then retrieved original paper death certificates from
the National Registry of Causes of Deaths, which has col-
lected data on dates and causes of death in Denmark since
1943 [25]. As recorded on the paper death certificate,
deaths were classified as either cardiac or non-cardiac,
based on underlying cause [17]. Cardiac death was defined
as an evident cardiac death, unwitnessed death or death
from unknown causes.
Patient characteristics
We obtained information on potential confounders (diabe-
tes, hypertension and obesity) from diagnoses recorded in
the DNRP [23] between 1977 and the index date.To ensure
complete identification of patients with diabetes, we also
searched the DNPD for any previous use of antidiabetic
drugs since 1995. From the WDHR [17], we retrieved
procedure-specific data, including the year of index PCI,
PCI indication (ST-segment elevation MI (STEMI), non-
STEMI or unstable angina pectoris (AP), or stable AP,
number of treated arteries (1, 2 or 3 or more), number of
implanted stents (1, 2 or 3 or more), lesion type (A, B or C)
[26], and stent type (drug-eluting or bare-metal stent). We
used the DNPD to obtain information on use of the follow-
ing medications: aspirin, calcium channel blockers, proton
pump inhibitors, vitamin K antagonists, non-selective non-
steroidal anti-inflammatory drugs, cyclo-oxygenase-2
selective inhibitors and systemic glucocorticoids. Associ-
ated ICD and ATC codes are provided in the Appendix.
Statistical analysis
We characterized the patients using medical, procedural,
and demographic variables. We followed all patients from
the index date until the date of MACE, non-cardiac death,
emigration, or 12 months of follow-up, whichever came
first. We examined the proportions of clopidogrel and
statin users that were covered at end of follow-up by the
last redeemed prescription. We stratified the analyses
according to whether patients had initiated therapy before
index PCI or not.
The time-varying exposure assessment allowed a
patient to be considered exposed to different medications
over time: clopidogrel plus a statin, clopidogrel without a
statin, a statin without clopidogrel or no use of clopidogrel
or a statin. This approach permitted comparison of the
MACE frequency per cumulative time-at-risk associated
with each of the four exposure categories.
We examined whether CYP3A4-metabolizing statins
modified the association between clopidogrel and MACE,
by comparing current use of clopidogrel with non-use, in
subgroups of patients with or without concomitant statin
use. We used Cox proportional hazards regression to
compute hazard ratios (HRs) with 95% confidence intervals
(CIs). The ‘interaction effect’ is the exponentiated coeffi-
cient for the interaction term in the model, that is, the ratio
of the stratum-specific HRs [16].The interaction effect esti-
mates the relative hazard rate increase in patients with
concomitant use of clopidogrel and a statin, beyond that
expected from the independent effects of each drug alone
[16]. An interaction effect different from 1.0 suggests that
concomitant statin use modifies any protective effect of
clopidogrel. We used the Wald c2 test to assess the null
hypothesis of no interaction.
In regression analyses, we adjusted for the following
potential confounders: age, gender, diabetes, hyperten-
sion, obesity, and time-varying use (calculated from the
number of days exposed) of aspirin and the potential
clopidogrel-interacting drugs of calcium channel blockers
and proton pump inhibitors [2].To examine the confound-
ing impact of our measures of diabetes, hypertension, and
obesity, we fitted a minimally adjusted model without
these variables. The results from the minimally adjusted
model were similar to those from the fully adjusted model
and are therefore not further reported. We repeated the
analyses stratifying by age, gender, PCI indication, stent
type and presence/absence of diabetes. We repeated the
analyses for the most commonly used statins in the data-
base (simvastatin and atorvastatin) and the individual out-
comes separately. Due to few events of stent thrombosis
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and ischaemic stroke, we do not report further on these
outcomes.
Finally, we also examined whether clopidogrel modi-
fied the association between statin use and MACE, by com-
paring current statin use with non-use, in subgroups of
patients with or without concomitant clopidogrel use. To
examine the impact of new use and longer term statin use
starting before the PCI date [27], we repeated the analysis
in subgroups of patients with or without one or more filled
statin prescriptions before index PCI. The results were




We identified 13 001 patients who had undergone coro-
nary stent implantation (Table 1). The median age on the
index date was 64 years and 27.7% were female. The indi-
cations for PCI were STEMI for 3790 (29.2%) patients, non-
STEMI or unstable AP for 3987 (30.7%) patients and stable
AP for 4876 (37.5%) patients. During follow-up, 11 859
(91%) patients filled at least one prescription for clopi-
dogrel and 9685 (74%) filled at least one prescription for a
CYP3A4-metabolizing statin. Among patients using clopi-
dogrel after PCI,only 45% continued treatment until end of
follow-up. This proportion was 84% among statin users
(Table 2).
Clinical outcomes
Overall 1890 (14.5%) patients experienced a MACE during
follow-up. Among these patients, those who did not use
one drug at time of outcome tended also not to use the
other (Table 3). The rates of MACE per 1000 person years
were 104 for clopidogrel plus CYP3A4-metabolizing statin
use, 130 for clopidogrel without statin use, 108 for statin
without clopidogrel use and 446 for no use of either drug
(Table 3). The adjusted HR for MACE comparing clopi-
dogrel use with non-use was 0.68 (95% CI 0.58, 0.79)
among statin users and 0.34 (95% CI 0.29, 0.40) among
statin non-users, yielding an interaction effect of 1.97 (95%
CI 1.59, 2.44, P < 0.0001).The results were consistent for MI,
TLR or cardiac death as separate outcomes (Table 4).
We observed no substantial difference from the overall
results when stratifying by age, gender, stent type,
presence/absence of diabetes (data not shown). Stratifying
on PCI indication, the adjusted HR for MACE comparing
clopidogrel use with non-use among STEMI patients was
0.68 (95% CI 0.58, 0.79) among CYP3A4-metabolizing
statin users and 0.34 (95% CI 0.29, 0.40) among statin non-
users (interaction effect = 2.24, 95% CI 1.49, 3.36). Among
patients with non-STEMI or unstable AP, these were 0.66
(95% CI 0.48, 0.91) and 0.30 (95% CI 0.22, 0.40), respectively
(interaction effect = 0.99, 95% CI 0.68, 1.43), and among
those with stable AP, 0.89 (95% CI 0.69, 1.16) and 0.51 (95%
CI 0.37, 0.71), respectively (interaction effect = 1.75, 95% CI
1.17, 2.62).
The adjusted HR for MACE comparing statin use with
non-use, was 0.97 (95% CI 0.83, 1.13) among clopidogrel
users and 0.49 (95% CI 0.42, 0.57) among clopidogrel non-
users (Table 5). Results for simvastatin and atorvastatin use
were similar to those associated with statin use overall
(Tables 3–5).
Discussion
In this population-based cohort study of 13 001 patients
undergoing PCI, clopidogrel and CYP3A4-metabolizing
statin use were each associated with a markedly reduced
rate of MACE within 12 months after coronary stent
implantation. When used concomitantly, each drug modi-
fied modestly the magnitude of the protective effect of
the other. Of major clinical importance, however, statin use
was not associated with any increased cardiovascular risk
in patients using clopidogrel after coronary stent
implantation.
Our study adds important information about the clini-
cal implications of the clopidogrel–statin interaction. In
several ex vivo studies, atorvastatin [3–5] and simvastatin
[6] were reported to diminish the antiplatelet effect of clo-
pidogrel. Furthermore, the inhibitory effect by atorvastatin
appeared dose-dependent [4, 5]. However, other studies
did not support these findings [28–39], in particular when
measurements of clopidogrel’s antiplatelet effect were
made several weeks after onset of statin co-administration
[31–34] or when the statin examined was atorvastatin [35,
36]. High loading doses of clopidogrel (600 mg) could in
some of the ex vivo studies, however, have masked any
statin-mediated reduction in the antiplatelet effect of clo-
pidogrel [37–39].The conflicting results and methodologi-
cal limitations due to small sample sizes and different drug
doses, measurement techniques and protocols make the
ex vivo data inconclusive [2].
Several studies have sought to address whether the
potential pharmacokinetic interaction between clopi-
dogrel and statins is of clinical importance. A Canadian
study of 2927 patients found concomitant use of ator-
vastatin and clopidogrel associated with a 1.65-fold
(95% CI 1.07, 2.54) increased risk for MACE within 30 days
after PCI, compared with use of clopidogrel alone [40].
Other CYP3A4-metabolizing drugs were associated with
similar risks [40]. In a subsequent analysis of 10 491
patients with a 90 days follow-up, the HR for adverse out-
comes associated with concomitant use of CYP3A4-
metabolized statins was reduced to 1.16 (95% CI 0.91,
1.47) when the reference group was non-CYP3A4
metabolized statins [15]. Also, a study of 211 patients
treated with clopidogrel before PCI reported a lower rate
of periprocedural MI for patients treated with pravastatin
M. Schmidt et al.
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or fluvastatin compared with atorvastatin or simvastatin.
Contrasting these findings, a randomized controlled trial
[7], post hoc analyses of the CREDO, CHARISMA and
PROVE IT–TIMI trials [8–10] and registry-based studies
[11–15] did not support any substantial adverse outcome
associated with co-administration of lipophilic statins and
clopidogrel. Whereas some of these studies reported no
increased risk [11–13], others reported only non-
significant increased risks (comparing atorvastatin with
pravastatin or no statin use [8, 9, 14] or comparing CYP-
metabolized statins with non-CYP metabolized statins [8,
9, 15].
Table 1
Characteristics of the entire stent cohort and the subgroup experiencing major adverse cardiovascular events (MACE)
All patients (n = 13 001) MACE patients* (n = 1 890)
n (%) (%)
Female 3 599 (27.7) 533 (28.2)
Age group
<60 years 4 763 (36.6) 585 (31.0)
60–69 years 3 949 (30.4) 825 (27.9)
70 years 4 289 (33.0) 777 (41.1)
Medication use†
Clopidogrel 11 859 (91.2) 1 097 (58.0)
Statins 9 685 (74.5) 759 (40.2)
Simvastatin 8810 (67.8) 673 (35.6)
Lovastatin 42 (0.3) 3 (0.2)
Atorvastatin 1243 (9.6) 96 (5.1)
Aspirin 11 231 (86.4) 906 (47.9)
Vitamin K antagonists 889 (6.8) 93 (4.9)
Non-selective NSAIDs 1 409 (10.8) 75 (4.0)
COX-2 inhibitors 1 322 (10.2) 78 (4.1)
Oral glucocorticoids 943 (7.3) 70 (3.7)
Calcium channel blockers 3 016 (23.2) 244 (12.9)
Proton pump inhibitors 2 742 (21.1) 271 (14.3)
Comorbidities‡
Diabetes 1 390 (10.7) 267 (14.1)
Hypertension 389 (3.0) 76 (4.0)
Obesity 82 (0.6) 12 (0.6)
Procedure data
Year of study entry
2002 3 112 (23.9) 496 (26.2)
2003 3 722 (28.6) 561 (29.7)
2004 3 986 (30.7) 542 (28.7)
2005 2 181 (16.8) 291 (15.4)
PCI indication
STEMI 3 790 (29.2) 862 (45.6)
Non-STEMI or unstable AP 3 987 (30.7) 508 (26.9)
Stable AP 4 876 (37.5) 461 (24.4)
Other 348 (2.7) 59 (3.1)
Number of treated arteries§
1 10 184 (78.3) 1 472 (77.9)
2 2 366 (18.2) 356 (18.8)
3 339 (2.6) 47 (2.5)
Number of stents§
1 10 761 (82.8) 1 483 (78.5)
2 1 720 (13.2) 308 (16.3)
3 458 (3.5) 93 (4.9)
Lesion type§¶
A 2 684 (20.6) 310 (16.4)
B 7 884 (60.6) 1 200 (63.5)
C 2 427 (18.7) 380 (20.1)
Stent type
BMS 8 847 (68.0) 1 428 (75.6)
DES 3 548 (27.3) 378 (20.0)
BMS and DES 606 (4.7) 84 (4.4)
*Patients with myocardial infarction, ischaemic stroke, stent thrombosis, target lesion revascularization or cardiac death during the 12 month follow-up period. †Any prescription
filling during follow-up. ‡Registered between 1977 and the index PCI. §Data were not available on the number of treated arteries for 112 patients, on the number of stents for
62 patients, and on the lesion type for 6 patients. ¶Lesion classification (simplified): A = non-complicated, length <10 mm, B = irregular, length 10–20 mm, C = irregular, sidebranch,
90 degrees, chronic occlusion, length >20 mm [26]. AP angina pectoris, BMS bare-metal stent, COX cyclo-oxygenase, DES drug-eluting stent, NSAIDs non-steroidal anti-inflammatory
drugs, PCI percutaneous coronary intervention, STEMI ST-segment elevation myocardial infarction.
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One major limitation of all previous clinical outcome
studies [7–15] was an inability to quantify the isolated
interaction effect [16]. Initiating clopidogrel therapy may
not be a valid proxy for exposure status throughout follow-
up, because patients may stop and restart treatment or
may discontinue completely before the end of the recom-
mended treatment period, for example due to intolerable
side effects, as it was seen for a large proportion of the
clopidogrel-using patients. To quantify the actual interac-
tion effect [16], it is therefore necessary to examine and
compare the rate of MACE associated with use of clopi-
dogrel alone, clopidogrel plus a statin, a statin alone or
neither. Through our time-varying exposure ascertain-
ment, we thus avoided the assumption that once a patient
initiated a medication it was continued for the remainder
of its recommended treatment period.
Our study supports both ex vivo studies [3–6] reporting
an attenuated antiplatelet effect of clopidogrel due to con-
comitant statin use and clinical outcome studies report-
ing no increased risk of co-administering statins to
clopidogrel-treated patients [2, 41]. This fact is likely
explained by the protective effects of statins themselves.
Independent of their beneficial lipid lowering effects,
statins are reported also to reduce morbidity and mortality
after coronary stent implantation through anti-oxidative,
anti-inflammatory and anti-thrombotic properties [42].
These so called ‘pleiotropic’ effects thus may improve
endothelial function, stabilize atherosclerotic plaques,
decrease oxidative stress and minimize the thrombogenic
response [42]. While stents deal effectively with the
mechanical aspects of atherosclerosis, statins play an
important role in reducing the progression of the athero-
sclerotic process itself. In our study, the rate of MACE
among statin users was similar to that among patients
using both clopidogrel and a statin. Our results thus
support that statins should not be withheld from patients
with appropriate indications due to concerns for a poten-
tial interaction with clopidogrel.
Strength and limitations
A number of issues should be considered when interpret-
ing our results. The population-based design within the
setting of a tax-supported universal healthcare system
largely eliminated selection biases. Data in the prescription
database are virtually complete [20]. Although we had to
use prescription data as a proxy for actual drug use, we
based drug exposure information on actual dispensing at
pharmacies [20]. Copayment requirements increased the
likelihood of compliance. We were able to calculate the
number of days exposed from the number of days of medi-
cation supplied, increasing the accuracy of exposure infor-
mation [43]. Although relying on assumptions regarding
the use of dispensed medications, these advanced
methods of defining exposure reduced the likelihood of
non-differential misclassification [44]. A limitation was that
the prescribed daily dose of statins was not available. Also,
individuals who continue to use drugs such as statins for
prolonged periods are likely to be particularly healthy [45].
This can distort findings regarding the effects of the drugs,
but we were able to confirm that this potential bias did not
affect our findings by studying statin ‘new users’ [27]. On
the other hand, discontinuation of statins might be associ-
ated with poor health [45], but the low rate of statin dis-
continuation we observed implies that our findings are
unlikely to be biased in this way.
Use of the WDHR and DNRP data to ascertain study
outcomes has previously been validated [17, 24] and the
DNPD has been shown to be accurate and complete [20].
Information on drug use and hospitalizations were col-
lected independently from medical databases, avoiding
Table 2
The proportion of clopidogrel and statin users who continued therapy until the end of follow-up*
No
Drug use at end of follow-up*
No (%) Yes (%)
Ever use of clopidogrel after PCI† 11 859 6 557 (55.3) 5 302 (44.7)
Ever use of clopidogrel before PCI‡ 1 698 811 (47.8) 887 (52.2)
No clopidogrel prescription before PCI 10 161 5 746 (56.5) 4 415 (43.5)
No clopidogrel prescription after PCI 1 142 1 102 (96.5) 40 (3.5)§
Ever use of clopidogrel before PCI‡ 169 129 (76.3) 40 (23.7)§
No clopidogrel prescription before PCI 973 973 (100) –
Ever use of a CYP3A4-metabolizing statin after PCI† 9 685 1 519 (15.7) 8 166 (84.3)
Ever use of a statin before PCI‡ 4 387 662 (15.1) 3 725 (84.9)
No statin prescription before PCI 5 298 857 (16.2) 4 441 (83.8)
No CYP3A4-metabolizing statin prescription after PCI 3 316 3 171 (95.6) 145 (4.4)
Ever use of a statin before PCI‡ 461 316 (68.5) 145 (31.5)
No statin prescription before PCI 2 855 2 855 (100) –
*End of follow-up was defined by a major adverse cardiovascular event, non-cardiac death, emigration or 12 months of follow-up, whichever came first. Patients were considered
drug users at end of follow-up if they were covered by the number of days exposed from their last prescription redemption. †At least one prescription redemption within follow-up.
‡At least one prescription redemption within 5 years before PCI. §Patients who at time of death were covered by the number of days exposed from their last prescription redemption
before PCI and who did not live to fill a new prescription after PCI. PCI percutaneous coronary intervention.
M. Schmidt et al.
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reliance upon self-reporting and thus reducing the poten-
tial for differential misclassification. We note that we
observed higher protective effects of clopidogrel and
statins than reported in clinical trials [46, 47]. However,
population-based effects may differ from those seen in
selected trial participants. Moreover, intention to treat
analysis in randomized controlled trials is generally conser-
vative. Nonetheless, we cannot rule out confounding from
unmeasured variables such as tobacco and alcohol use or
residual confounding from unregistered diabetes, hyper-
tension or obesity.
In conclusion, we found that clopidogrel and statin use
was individually associated with a markedly reduced rate of
MACE within 12 months after coronary stent implantation.
Although we observed an interaction between use of clo-
pidogrel and CYP3A4-metabolizing statins, use of statins
in addition to clopidogrel was not associated with an
increased rate of MACE,implying that statins should remain
a recommended lipid-lowering therapy for these patients.
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Appendix
ATC codes defining drug use
Clopidogrel: B01AC04
Statins: simvastatin: C10AA01; lovastatin: C10AA02; atorv-
astatin: C10AA05.
Aspirin: B01AC06, N02BA01, N02BA51, B01AC30
Vitamin K antagonists: B01AA03, B01AA04
Non-selective non-steroidal anti-inflammatory drugs:
M01AB01, M01AC01, M01AE01, M01AE51, M01AE02,
M01AE03, M01AE53, M01AE14, M01AG02
Cyclo-oxygenase-2 selective inhibitors: M01AH, M01AB05,
M01AB55, M01AB08, M01AC06, M01AX01
Systemic glucocorticoids: H02AB
Proton pump inhibitors: A02BC01-5
Calcium channel blockers: C08CA01, C08CA02, C08CA03,
C08CA05, C08CA08, C08CA09, C08CA13, C08CX01,
C08DA, C08DB01.
ICD and ATC codes defining diseases
Myocardial infarction: ICD-10 code: I21
Ischaemic stroke: ICD-10 codes: I63-64
Diabetes: ICD-8 codes: 249, 250; ICD-10 codes: E10-14, O24,
H36.0; ATC codes: A10A, A10B
Obesity: ICD-8 codes: 277, 279.00, 279.01: ICD-10 codes:
E65, E66, E67, E68
Table 5








effect† (95% CI) P‡
Overall¶
-Clopidogrel 0.45 (0.38, 0.52)
2.03 (1.64, 2.51) <0.0001
0.49 (0.42, 0.57)
1.97 (1.59, 2.44) <0.0001
+Clopidogrel 0.90 (0.78, 1.05) 0.97 (0.83, 1.13)
Simvastatin
-Clopidogrel 0.47 (0.40, 0.55)
1.87 (1.51, 2.32) <0.0001
0.47 (0.40, 0.55)
1.95 (1.57, 2.41) <0.0001
+Clopidogrel 0.87 (0.76, 1.01) 0.91 (0.79, 1.05)
Atorvastatin
-Clopidogrel 0.67 (0.49, 0.91)
1.68 (1.13, 2.51) 0.01
0.68 (0.50, 0.92)
1.65 (1.10, 2.46) 0.01
+Clopidogrel 1.13 (0.87, 1.46) 1.12 (0.86, 1.46)
*Composite of myocardial infarction, ischaemic stroke, stent thrombosis, target lesion revascularization and cardiac death. †The ratio of the stratum specific hazard ratios, which
estimates the relative hazard rate increase associated with concomitant use of clopidogrel and statins, beyond that expected from the independent effects of these drugs alone.
‡Wald c2 test for no interaction in the adjusted model. §Adjusted for age, gender, diabetes, hypertension, obesity and time-varying use of aspirin, proton pump inhibitors and calcium
channel blockers. ¶Current use of simvastatin, lovastatin and atorvastatin.
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